Key Takeaways
- Shares of Veeva Systems currently trade near $285, with Wall Street projecting potential gains of 30% within the next year.
- The firm is transitioning clients from Salesforce infrastructure to its proprietary Veeva Vault CRM solution, with 14 of the world’s top 20 biopharma companies already on board.
- Second fiscal quarter revenue reached $928 million, marking an 18% year-over-year increase, prompting management to lift full-year projections to approximately $3.7 billion.
- The company’s Falcon platform leverages agentic AI to streamline medical and regulatory processes, potentially reducing manual workflows by as much as 70%.
- French pharmaceutical giant Servier is implementing Veeva OpenData in over 80 countries to create a comprehensive, AI-compatible data infrastructure.
Veeva Systems shares finished trading at $285.45 on September 30, 2026. While this represents a significant decline from the 2021 peak of $344, several market analysts believe the stock has substantial room for recovery and growth.
This enterprise software provider specializes in solutions for pharmaceutical and biotechnology organizations. Its platform encompasses clinical research management, regulatory submission processes, and commercial sales force automation.
The firm commands over 80% of the market for biopharma customer relationship management solutions. This represents a commanding presence within a specialized sector that flies under the radar for most investors.
Breaking Free from Salesforce Dependency
Historically, Veeva’s applications operated on Salesforce’s underlying technology stack. Beginning in 2024, the organization initiated development of Vault CRM, a proprietary alternative, and commenced client migration efforts.
This strategic transition enables Veeva to improve profitability through better margin control and eliminates dependence on a rival’s technology foundation. The move grants complete autonomy over product development and infrastructure decisions.
To date, 14 out of the 20 largest biopharma enterprises worldwide have signed on for Vault CRM. This adoption rate demonstrates substantial confidence in the platform’s capabilities.
Wells Fargo’s Stan Berenshteyn maintains an Overweight rating with a $330 price objective. He highlights fresh CRM contract wins and accelerating momentum in the data cloud segment as key factors supporting his bullish stance.
Advancing with AI Agents
The company’s latest innovation, the Falcon suite, focuses on executing complex, multi-stage processes with minimal human intervention.
Falcon MLR currently operates in production, automating the review of marketing materials for medical, legal, and regulatory compliance. Additional agents addressing clinical operations, regulatory submissions, and pharmacovigilance are scheduled for release through 2027.
According to Veeva’s internal assessments, these automation capabilities could eliminate up to 70% of certain repetitive tasks. The company further suggests drug development cycles might accelerate by 30% to 90% when utilizing its technology stack.
Gartner forecasts that worldwide investment in specialized AI agents will more than double annually through 2029. This projection indicates a 119% compound annual growth rate, ultimately exceeding $750 billion in market value.
For the fiscal second quarter, Veeva posted revenue of $928 million, reflecting 18% growth compared to the prior year period. Adjusted earnings per share reached $2.35, likewise advancing 18%.
Management elevated its full-year revenue forecast to approximately $3.7 billion. This represents the third upward adjustment in the current fiscal year.
Full-year adjusted earnings per share guidance now stands near $9.21, indicating 14% year-over-year expansion. Leadership has established a $6 billion annual revenue milestone target for 2030.
Achieving this objective would require maintaining roughly 18% average annual growth over the coming three years. The target was initially established in 2023, predicated on anticipated market share expansion across core product categories.
The stock currently trades at approximately 27 times forward earnings estimates. This valuation exceeds both the broader equity market and Salesforce’s 14 times multiple, though it remains below Veeva’s five-year historical average of 35 times.
Veeva consistently generates operating margins exceeding 45%. When combined with revenue growth approximating 15%, the company significantly surpasses the software industry’s “Rule of 40” performance threshold.
The balance sheet carries no debt obligations. Principal risks include potential execution challenges during the ongoing Salesforce platform migration and broader market sentiment shifts regarding AI-focused equities.
On September 30, Veeva disclosed that Servier, a French pharmaceutical corporation, is deploying Veeva OpenData on a global scale. Servier plans to unify customer reference information across more than 80 markets to establish what management describes as an AI-optimized data infrastructure.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
